QZQiansen Zhang

Qiansen Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiansen Zhang has a total of 372 co-authors. Here are the top co-authors by number of shared publications:

  • Mingyao Liu

    Institute of Medical Science, University of Toronto, Toronto, Canada; Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, Canada, Canada

    21 shared publications
  • Yihua Chen

    School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products and Yunnan College of Modern Biomedical Industry, Kunming Medical University, Kunming, Yunnan, 650500, China

    15 shared publications
  • Zhengfang Yi

    East China Normal University

    14 shared publications
  • Huaiyu Yang

    Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China

    13 shared publications
  • Huang Chen

    East China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China

    13 shared publications
  • Shifen Xu

    Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    13 shared publications

Latest Publications

  • Histone succinylation by NCOA1/2/3 drives mediator association and transcription

    by Wei Wei, Zhongye Dai, Lei Shu, Meilin Sun, Doug W. Chan, Bingbing Hao, Jingdong Xue, Jing Luo, Xixia Yuan, Song Gao, et al.

  • Disruption of cellular iron homeostasis by SRPX2-IRP1 interaction aggravates renal fibrosis in chronic kidney disease

    by Peiran Yin, Lumiao Chen, Mengyang Ding, Zhaonan Wei, Anran Huo, Yinfang Wang, Mengjun Xie, Hu Zhang, Yuan Qin, Haozhe Ding, et al.

    Disrupted iron homeostasis is a critical pathological feature of chronic kidney disease (CKD) and drives renal fibrosis and disease progression, but the underlying regulatory mechanisms linking iron dysregulation to renal fibrosis remain poorly defined. Here, we identify sushi repeat-containing protein X-linked 2 (SRPX2) as a novel pathogenic regulator of renal fibrosis that dysregulates tubular cellular iron metabolism. Clinical validation revealed that SRPX2 expression was significantly elevated in kidney biopsy tissues and serum samples of CKD patients with various renal pathological types, serving as a potential biomarker for CKD progression. In two classic mouse renal fibrosis models of unilateral ureteral obstruction (UUO) and folic acid (FA)-induced nephropathy, as well as in TGF-β1-stimulated human renal tubular epithelial HK-2 cells, SRPX2 was significantly upregulated in a time- and dose-dependent manner through the TGFβR1/SMAD2/3 signaling pathway. Global and TEC-specific ablation of Srpx2 was sufficient to attenuate kidney injury and fibrosis. Mechanistically, SRPX2 physically interacted with iron regulatory protein 1 (IRP1), a central coordinator of cellular iron homeostasis. This interaction disrupted the IRP1/iron-responsive element regulatory system, leading to decreased expression of iron import protein (TFR1) and increased expression of iron storage (FTH1) and export (FPN) proteins, ultimately triggering intracellular iron dyshomeostasis. Moreover, proteomic and transcriptional profiling of clinical CKD samples and UUO mouse kidneys further confirmed the significant dysregulation of iron ion metabolism during renal fibrosis progression. Notably, therapeutic iron dextran supplementation alleviated UUO-induced renal fibrosis. Collectively, our findings reveal SRPX2 as a key pathogenic factor driving renal fibrosis by disrupting tubular iron homeostasis. Targeting the SRPX2-IRP1 regulatory axis presents a promising therapeutic strategy for slowing CKD progression.

  • Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer

    by Yuzhan Li, Yaxun Guo, Dazhao Mi, Fubing Li, Jingfeng Song, Qiansen Zhang, Ceshi Chen, Zhigang Yu, Yihua Chen

  • Open Access

    Structural mechanisms for self-activation of protease-activated receptor 4 by tethered ligand

    by Zhikang Xu, Jiacheng He, Zihan Zhou, Zhefan Yu, Yingnan Zhang, Anqi Chen, Xiaolei Chai, Mingyao Liu, Jian Zhang, Qiansen Zhang, et al.

  • Open Access

    Structural insights into measles virus RNA synthesis regulation and pan-paramyxoviral polymerase inhibition by ERDRP-0519

    by Tianjiao Du, Jiening Wang, Chengji Yang, Rubing Xue, Ying Chen, Kaiyue Jie, Xiaokang Zhang, Long Zhang, Gaojie Song, Qiansen Zhang, et al.

    Nonsegmented negative-sense RNA viruses (nsNSVs) rely on a multifunctional RNA-dependent RNA polymerase (RdRP) complex for transcription and replication. In measles virus (MeV), the nonstructural protein C has long been implicated in regulating RNA synthesis, yet its precise role remains unclear. Here, we show that the MeV C protein directly associates with the RdRP complex. Using cryoelectron microscopy, we determined atomic-resolution structures of the MeV polymerase with and without C, revealing that C binding stabilizes the C-terminal region of L and locks the complex into a replication-competent elongation state. Biochemical data further show that C promotes N protein recruitment, enhancing polymerase processivity through facilitating encapsidation during replication. Additionally, we also resolved high-resolution structures of MeV and Nipah virus (NiV) polymerases bound to ERDRP-0519, an orally available morbillivirus inhibitor. Unexpectedly, the compound occupies an allosteric pocket within the RdRp domain rather than the previously predicted PRNTase domain, overlapping conserved resistance sites. This binding induces conformational changes in palm subdomain, blocking RNA template and nucleotide engagement, thereby halting RNA synthesis. These findings uncover distinct regulatory and inhibitory mechanisms in paramyxovirus polymerases and provide a structural framework for the rational design of broad-spectrum antivirals targeting MeV, NiV, and potentially other clinically relevant nsNSVs.


  • Open Access

    Supplementary Figures S1-S13 from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

    by Huang Chen, Wenbo Zhou, Aiwu Bian, Qiansen Zhang, Ying Miao, Xuan Yin, Jiangnan Ye, Shifen Xu, Chaowen Ti, Zhenliang Sun, et al.

    Fig. S1. Structure-based ligand discovery of STAT3 inhibitorsFig. S2. Surface plasmon resonance analysis of interactions between WB436B to STATfamily proteinsFig. S3. The biology evaluation of WB436B inactive analogue WB345Fig. S4. The mutation in STAT3 SH2 domain directly inhibited STAT3 transcriptionalactivitiesFig. S5. WB436B induced pancreatic cancer cells apoptosisFig. S6. STAT3 knockdown reduced PDAC cells growth and colony formationFig. S7. WB436B displayed little cytotoxicity to STAT3 stable knockdown PDAC cells.Fig. S8. STAT3 depletion inhibited the growth of PDAC cellsFig. S9. WB436B suppressed STAT3 nuclear translocation and the binding to the targetgenes in pancreatic cancer cellsFig. S10. WB436B was well-tolerated in vivoFig. S11. WB436B was well-tolerated in pancreatic cancer metastatic mouse model.Fig. S12. WB436B inhibited PDAC tumor metastasis in vivoFig. S13. WB436B decreased PDAC tumors angiogenesis, inhibited tumor-associatedmacrophage infiltration and induced apoptosis in vivo

  • Open Access

    Supplementary Tables S1-S6 from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

    by Huang Chen, Wenbo Zhou, Aiwu Bian, Qiansen Zhang, Ying Miao, Xuan Yin, Jiangnan Ye, Shifen Xu, Chaowen Ti, Zhenliang Sun, et al.

    Table S1. List of antibodies used and their technical information Table S2. The sequence of Real-time PCR primersTable S3. The sequence of shRNAs for silencing STAT3 Table S4. The sequence of ChromatinImmunoprecipitation (Ch-IP) PCRTable S5. The binding affinities of WB436B towards STAT member protein in SPR assay Table S6. Selectivity profiling of WB436B in a kinase panel

  • Open Access

    Supplementary Methods from Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

    by Huang Chen, Wenbo Zhou, Aiwu Bian, Qiansen Zhang, Ying Miao, Xuan Yin, Jiangnan Ye, Shifen Xu, Chaowen Ti, Zhenliang Sun, et al.

  • A conserved H3K14ub-driven H3K9me3 for chromatin compartmentalization

    by Yuanyong Huang, Yimei Sun, Hongyun Qi, Quanlong Jiang, Jialun Li, Mingzhi Chang, Xinyan Li, Lei Shu, Xiaoya Duan, Yiqin Wang, et al.

    Compartmentalization of eukaryotic genome into euchromatin and heterochromatin is of critical biological significance1,2,3. Previous studies have suggested a self-templating pathway involving the reading and writing of histone H3 lysine 9 methylation by SUV39H as the core mechanism for heterochromatin reassembly during cell division1,3. In fission yeast, the mammalian SUV39H homologue Clr4 forms a complex containing ubiquitin ligase Cul4, which catalyses H3K14 mono-ubiquitination (H3K14ub) to promote heterochromatin formation. However, whether heterochromatin reassembly in dividing mammalian cells involves a similar pathway is unknown. Here we identified G2E3 as an H3K14ub-specific, pericentromeric heterochromatin-localized E3 ligase. G2E3-catalysed H3K14ub potentiates histone H3 lysine 9 trimethylation (H3K9me3) by SUV39H and is specifically required for SUV39H compartmentalization and H3K9me3 in pericentromeric heterochromatin. Mechanistically, we found that G2E3 is highly expressed in G2/M phase and associates with mitotic chromosomes in an RNA-dependent manner to catalyse H3K14ub, which is essential for the subsequent sequential recruitment of SUV39H and HP1. The SUV39H chromodomain is a reader of dual H3K9me3 and H3K14ub modifications and SUV39H associates with pericentromeric heterochromatin primarily through its H3K14ub-binding activity. Notably, loss of G2E3 severely impairs pericentromeric heterochromatin organization and results in the aberrant accumulation of SUV39H and H3K9me3 in numerous euchromatin regions and widespread transcriptional repression. Thus, our findings revealed the H3K14ub-dependent SUV39H compartmentalization as a unified mechanism of pericentromeric heterochromatin formation, which is essential for proper euchromatin compartmentalization and transcriptional regulation.


  • Open Access

    Secondary structure transitions and dual PIP2 binding define cardiac KCNQ1-KCNE1 channel gating

    by Ling Zhong, Xiaoqing Lin, Xinyu Cheng, Shuangyan Wan, Yaoguang Hua, Weiwei Nan, Bin Hu, Xiangjun Peng, Zihan Zhou, Qiansen Zhang, et al.

    The KCNQ1 + KCNE1 potassium channel complex produces the slow delayed rectifier current (I Ks ) critical for cardiac repolarization. Loss-of-function mutations in KCNQ1 and KCNE1 cause long QT syndrome (LQTS) types 1 and 5 (LQT1/LQT5), accounting for over one-third of clinical LQTS cases. Despite prior structural work on KCNQ1 and KCNQ1 + KCNE3, the structural basis of KCNQ1 + KCNE1 remains unresolved. Using cryo-electron microscopy and electrophysiology, we determined high-resolution (2.5–3.4 Å) structures of human KCNQ1 APO , and KCNQ1 + KCNE1 in both closed and open states. KCNE1 occupies a pivotal position at the interface of three KCNQ1 subunits, inducing six helix-to-loop transitions in KCNQ1 transmembrane segments. Three of them occur at both ends of the S4–S5 linker, maintaining a loop conformation during I Ks gating, while the other three, in S6 and helix A, undergo dynamic helix-loop transitions during I Ks gating. These structural rearrangements: (1) stabilize the closed pore and the conformation of the intermediate state voltage-sensing domain, thereby determining channel gating, ion permeation, and single-channel conductance; (2) enable a dual-PIP2 modulation mechanism, where one PIP2 occupies the canonical site, while the second PIP2 bridges the S4–S5 linker, KCNE1, and the adjacent S6’, stabilizing channel opening; (3) create a fenestration capable of binding compounds specific for KCNQ1 + KCNE1 (e.g., AC-1). Together, these findings reveal a previously unrecognized large-scale secondary structural transition during ion channel gating that fine-tunes I Ks function and provides a foundation for developing targeted LQTS therapy.